ZimingSheng

Zimingsheng is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation cell therapies for cancer. The company's core focus is on off-the-shelf universal CAR-T (UCAR-T) technology, which aims to provide standardized, ready-to-use treatments that bypass the limitations of patient-specific autologous therapies. Utilizing its proprietary Z-CAR platform and advanced gene-editing tools, Zimingsheng develops products with improved safety and scalability. Its lead candidate, ZMS-001, is a CD19-targeted CAR-T therapy currently being evaluated in clinical trials for B-cell malignancies. The company is also advancing programs targeting BCMA for multiple myeloma and exploring applications in solid tumors. Zimingsheng is backed by prominent venture capital firms and maintains a robust R&D and manufacturing infrastructure in Beijing.